End-of-day quote
Ghana S.E.
03:30:00 06/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.05
GHS
|
0.00%
|
|
0.00%
|
0.00%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
20.4
|
18.13
|
12.94
|
12.94
|
13.72
|
10.98
|
Enterprise Value (EV)
1 |
23.85
|
20.3
|
18.27
|
23.95
|
29.3
|
26.15
|
P/E ratio
|
7.47
x
|
6.38
x
|
6.85
x
|
9.46
x
|
12
x
|
-3.11
x
|
Yield
|
-
|
4.8%
|
8.8%
|
5.82%
|
-
|
-
|
Capitalization / Revenue
|
1.25
x
|
0.9
x
|
0.56
x
|
0.63
x
|
0.61
x
|
0.54
x
|
EV / Revenue
|
1.46
x
|
1
x
|
0.79
x
|
1.16
x
|
1.29
x
|
1.28
x
|
EV / EBITDA
|
5.13
x
|
4.37
x
|
6.02
x
|
10.1
x
|
16.6
x
|
-9.9
x
|
EV / FCF
|
-16.2
x
|
-30.7
x
|
-2.6
x
|
-5.09
x
|
-6.92
x
|
14.8
x
|
FCF Yield
|
-6.17%
|
-3.26%
|
-38.5%
|
-19.6%
|
-14.5%
|
6.78%
|
Price to Book
|
2.05
x
|
1.25
x
|
0.73
x
|
0.76
x
|
0.75
x
|
0.74
x
|
Nbr of stocks (in thousands)
|
2,26,621
|
2,26,621
|
2,58,821
|
2,58,821
|
2,74,408
|
2,74,408
|
Reference price
2 |
0.0900
|
0.0800
|
0.0500
|
0.0500
|
0.0500
|
0.0400
|
Announcement Date
|
28/03/18
|
08/05/19
|
16/06/20
|
25/05/21
|
27/04/22
|
14/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
16.37
|
20.21
|
23.09
|
20.67
|
22.67
|
20.36
|
EBITDA
1 |
4.652
|
4.651
|
3.034
|
2.372
|
1.765
|
-2.642
|
EBIT
1 |
4.165
|
4.077
|
2.539
|
1.66
|
1.228
|
-3.207
|
Operating Margin
|
25.44%
|
20.18%
|
11%
|
8.03%
|
5.42%
|
-15.76%
|
Earnings before Tax (EBT)
1 |
3.251
|
3.536
|
2.3
|
1.363
|
1.432
|
-3.533
|
Net income
1 |
2.731
|
2.843
|
1.871
|
1.451
|
1.146
|
-3.509
|
Net margin
|
16.68%
|
14.07%
|
8.1%
|
7.02%
|
5.06%
|
-17.24%
|
EPS
2 |
0.0120
|
0.0125
|
0.007300
|
0.005287
|
0.004177
|
-0.0129
|
Free Cash Flow
1 |
-1.472
|
-0.6616
|
-7.026
|
-4.704
|
-4.235
|
1.773
|
FCF margin
|
-8.99%
|
-3.27%
|
-30.44%
|
-22.76%
|
-18.68%
|
8.71%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
0.003840
|
0.004400
|
0.002910
|
-
|
-
|
Announcement Date
|
28/03/18
|
08/05/19
|
16/06/20
|
25/05/21
|
27/04/22
|
14/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
3.45
|
2.17
|
5.33
|
11
|
15.6
|
15.2
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.7417
x
|
0.4673
x
|
1.756
x
|
4.642
x
|
8.829
x
|
-5.743
x
|
Free Cash Flow
1 |
-1.47
|
-0.66
|
-7.03
|
-4.7
|
-4.24
|
1.77
|
ROE (net income / shareholders' equity)
|
31.9%
|
23.3%
|
11.6%
|
8.14%
|
6.33%
|
-21.2%
|
ROA (Net income/ Total Assets)
|
15.9%
|
10.8%
|
5.57%
|
3.06%
|
1.83%
|
-4.29%
|
Assets
1 |
17.22
|
26.25
|
33.61
|
47.41
|
62.63
|
81.72
|
Book Value Per Share
2 |
0.0400
|
0.0600
|
0.0700
|
0.0700
|
0.0700
|
0.0500
|
Cash Flow per Share
2 |
0
|
0.0100
|
0
|
0
|
0
|
0
|
Capex
1 |
1.24
|
1.81
|
5.34
|
3.92
|
7.16
|
2.42
|
Capex / Sales
|
7.59%
|
8.98%
|
23.14%
|
18.95%
|
31.57%
|
11.89%
|
Announcement Date
|
28/03/18
|
08/05/19
|
16/06/20
|
25/05/21
|
27/04/22
|
14/04/23
|
|
1st Jan change
|
Capi.
|
---|
| 0.00% | 924K | | +47.58% | 765B | | -6.23% | 354B | | +20.36% | 331B | | +9.56% | 299B | | +18.87% | 248B | | -1.96% | 219B | | +11.11% | 216B | | +5.23% | 164B | | -2.29% | 162B |
Other Pharmaceuticals
|